Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06599229 · ClinicalTrials.gov registry record
Perfusion Abnormalities in Hypertrophic Cardiomyopathy
A clinical trial, sponsored by University of Virginia.
- Active
- Registry status
- 30
- Enrollment target
NCT06599229: Active study, sponsored by University of Virginia.
NCT06599229 is a clinical trial that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06599229 is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
Primary Outcome
Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)
Interventions
- DIAGNOSTIC_TEST myocardial contrast echo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2026-12-01 |
What the registry record for NCT06599229 still lists
NCT06599229 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which myocardial contrast echo is the first listed.
NCT06599229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06599229 about?
NCT06599229 is a clinical study titled "Perfusion Abnormalities in Hypertrophic Cardiomyopathy". The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
What is the current status of trial NCT06599229?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2025-01-02. Estimated completion is 2026-12-01.
What interventions are being tested in trial NCT06599229?
The interventions under investigation include: myocardial contrast echo (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06599229?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI